Activity of teicoplanin in localized experimental infections in rats.
We tested the ability of teicoplanin alone and in combination with rifampicin or gentamicin to cure experimental endocarditis and granuloma pouch infections in rats caused by Streptococcus faecalis, Str. sanguis, methicillin-sensitive and -resistant Staphylococcus aureus. Vancomycin and ampicillin were also tested. Teicoplanin was more active than vancomycin and ampicillin. Combinations of teicoplanin with rifampicin or gentamicin were significantly more effective than single drug therapy. These results suggest that teicoplanin could be an interesting alternative to vancomycin in the treatment of serious streptococcal and staphylococcal infections in man.
Arioli
V
V
Berti
M
M
Candiani
G
G
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D005839:Gentamicins / Q000627:therapeutic use; D006020:Glycopeptides / Q000627:therapeutic use; D006099:Granuloma / Q000188:drug therapy*; D008297:Male; D008712:Methicillin / Q000494:pharmacology; D010403:Penicillin Resistance; D051381:Rats; D011916:Rats, Inbred F344; D012293:Rifampin / Q000627:therapeutic use; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D013290:Streptococcal Infections / Q000188:drug therapy*; D017334:Teicoplanin; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D006020:Glycopeptides; D017334:Teicoplanin; D014640:Vancomycin; D008712:Methicillin; D012293:Rifampin